US FDA approves nasal spray for migraines
Washington (AFP) - The US Food and Drug Administration has approved a fast-acting nasal spray from Pfizer designed to treat migraines, the US pharmaceutical giant said Friday. Pfizer said it expected the drug, marketed under the name Zavzpret, to be available in pharmacies in July 2023. "The FDA approval of Zavzpret marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications," Pfizer chief commercial officer Angela Hwang said in a statement. A Phase 3 study of the drug found that it delivered pain relief to some migrai...